PHAT (Phathom Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is a publicly traded Healthcare sector company. As of May 20, 2026, PHAT trades at $11.51 with a market cap of $908.42M and a P/E ratio of -3.77. PHAT moved +0.35% today. Year to date, PHAT is -27.43%; over the trailing twelve months it is +159.68%. Its 52-week range spans $2.21 to $19.50. Analyst consensus is strong buy with an average price target of $24.25. Rallies surfaces PHAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns PHAT stock?
Hedge funds tracked by Rallies that own PHAT include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phathom Pharmaceuticals, Inc. Common Stock.
PHAT Key Metrics
Key financial metrics for PHAT
Metric
Value
Price
$11.51
Market Cap
$908.42M
P/E Ratio
-3.77
EPS
$-3.03
Dividend Yield
0.00%
52-Week High
$19.50
52-Week Low
$2.21
Volume
186.89K
Avg Volume
0
Revenue (TTM)
$175.11M
Net Income
$-221.25M
Gross Margin
87.09%
Top Hedge Funds Holding PHAT
Orbimed Advisors holds 1.45M shares of PHAT, changed +0.00% as of Sep 30, 2024.
Hedge funds tracked by Rallies that own PHAT include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phathom Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for PHAT?
Yes. Rallies tracks hedge fund and 13F ownership data for PHAT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PHAT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PHAT. It does not provide personalized investment advice.
